Subcutaneous administration of midazolam in pediatric diagnostic procedures

Evaluation of the Optimal Dosage for the Efficacy of Submucosal Midazolam Administration to Induce Sedation in Children Undergoing Diagnostic Procedures

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20171030037093N20

Enrollment

Registered

2019-10-05

Start date

2019-10-24

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sedation during procedure.

Interventions

Intervention 1: Intervention group: The first intervention group received midazolam at a dose of 0.3 mg / kg. Intervention 2: Intervention group: The second intervention group received midazolam at a

Eligibility

Sex/Gender

All

Age

3 Months to 5 Years

Inclusion criteria

Inclusion criteria: The age range of over three months up to five years Children requiring diagnostic procedures such as CT scan

Exclusion criteria

Exclusion criteria: The patients with excessive sensitivity to Benzodiazepines Medical disorder of shock or blood pressure Alcohol intoxication Poor vital signs Pulmonary diseases Myasthenia gravis or musculoskeletal disorders

Design outcomes

Primary

Measure	Time frame
The length of the sedative effect. Timepoint: From the beginning of sedation to the return of the child to full consciousness. Method of measurement: Computing.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaeed Majidinejad

Esfahan University of Medical Sciences

saeedmajidinejad@yahoo.com+98 31 3792 7539

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026